

Analytical Methods

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

COMMUNICATION

Practical detection for simultaneous analysis of multiple antigens with Staphylococcal protein A as intermediate

Xiaomei Xie, Caiyun Wang, Qian Xiao, Yizhi Zheng, Yuqin Li and Bo Feng*

College of Chemical Engineering, Xiangtan University, Xiangtan 411105, Hunan Province, China

*Corresponding Author. Tel.: +86 731 58298259; Fax: +86 731 58298172.

E-mail address: fengbo@xtu.edu.cn; fengbo5460@hotmail.com

Abstract

Simultaneous measurements of multiple protein biomarkers are typically required to avoid false results in clinical diagnosis. In this work, we present an immunochemical event between antibody and antigen for simultaneous analysis of double biomarkers. In the presence of Staphylococcal protein A (SPA), two kinds of antibodies were captured on the Ni-NTA agarose beads in a site-oriented model. Two target antigens and fluorescence-labeled antibodies were then added in turn to form the immunosorbent complex (antibody-antigen-antibody). The standard sandwich immunoassay can be visualized using a fluorescence microscope to detect the respective fluorescence-labeled antibodies bound to the bead's surface. Meanwhile, a freshly prepared gold-coated substrate was modified with 3-aminopropyl triethoxysilane (APTES) through a glutaraldehyde linker. The immunosorbent complex of the SPA-antibody-antigen was also validated in a quartz crystal microbalance (QCM) apparatus. The results showed an appreciable increase in frequency shift when the SPA, antibody, and antigen bound onto the chip, respectively. Qualitative synchronous fluorescence and quantitative QCM biosensor were practical methods for simultaneous detection of multiple serological antigen biomarkers.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Detection of multiple protein biomarkers is necessary for making an exact diagnosis of disease and providing an effective subsequent treatment in clinical medicine.¹⁻³ For example, to minimize false-positive and false-negative in cancer diagnosis that can arise from population variations in expression of a single biomarker, simultaneous measurements of a panel of protein biomarkers are required, especially in cases when clinical symptoms are not differentiating.³⁻⁶ And likewise, the levels of these biomarkers at different stages of cancer development have important reference value for the guidance of clinical medication and personalized therapy.⁷⁻⁹

To date, most clinical diagnostic assays are conducted using an immobilized antibody as specific probe to determine the target biomarker. Traditional methods for protein biomarkers, such as hepatitis B virus surface antigen (HBsAg) and alpha fetoprotein (AFP), usually involve ELISA (enzyme-linked immunosorbent assay), which based on antigen-antibody specific binding and the enzymatic activity reporter.¹⁰ Recently, quantum dots (QDs) have widely used as the signal probes for the immunoassay based on their narrow emission spectra and highly sensitivity.^{11,12} For example, Jun Shen *et al.*¹¹ combined the advantages of quantum dots with immunochromatographic assay (ICA), which allowed the binding of HBsAg on quantum dot-beads, forming a sandwich ICA platform for ultrasensitive and quantitative detection of HBsAg in human serum. With the rise of nanotechnology, carbon nanotube-based electrochemical biosensors opened a promising approach to evaluate the interaction between antibody and antigen *in vitro*. H. Dai *et al.*¹³ introduced a new biosensor based on electrospun carbon nanotubes, wherein AFP antibody was bound to the functionalized electrospun nanofibers for fabricating immunosensor to detect AFP protein.

Simultaneous detection of multiple biomarkers needs different specific antibodies. In mammals, five antibody classes exist, including IgA, IgD, IgE, IgG, and IgM. Fortunately, nearly all antibodies used as probe are from IgG, which is made up of three fragments, namely, two Fab units that can bind specifically to the antigen and another Fc that is identical with the other. Staphylococcal protein A (SPA) can specifically recognize and bind this Fc unit, rendering Fab exposed and accessible to the target analyte, resulting in oriented immobilization of the antibody.¹⁴⁻¹⁷

The Ni-NTA bead is an affinity chromatography matrix for purifying recombinant proteins carrying a histidine (His) tag. Pull-down assays using Ni-NTA is also an effective tool to study protein-protein interactions.¹⁸ In the current study, we present a

1
2
3 modified method for detection of antigen-antibody interactions using a standard
4 affinity chromatography reagent. Binding events between antigen and antibody, which
5 are traced by fluorescent dye-labeled antibody, are visualized on single affinity
6 chromatography beads by fluorescence microscopy. The use of different fluorescent
7 dyes with different emission wave lengths allows for simultaneous analysis of
8 multiple target biomarkers in a single experiment. However, this method is hard to be
9 adaptable for large-scale setups and quantitative determination because of the
10 fluorescence quenching.

11
12
13 In recent years, quartz crystal microbalance (QCM)-based gravimetric
14 immunosensors with highly sensitive quantitative and real-time detection capabilities
15 have been used extensively. This technology enables the measurement of nanoscale
16 mass and structural changes, thereby offering a robust method for studying molecular
17 interaction. Measurements are based on changes in vibration frequency of a quartz
18 crystal sensor in response to interactions or reactions occurring on the sensor surface.
19 To further optimize the immunosensing performance of the gold electrode and to
20 avoid nonspecific interactions, a more reliable immobilization method for antibody
21 binding to SPA coated gold surface was used in this study.^{17,19} A silanization
22 chemistry with 3-aminopropyl triethoxysilane (APTES) is used to attach antibodies to
23 the gold surface with the help of a glutaraldehyde linker,²⁰⁻²² which will form a barrier
24 that prevents binding biomolecules from coming in contact with the metal surface.²²
25 Antibodies are first captured by the SPA immobilized on the electrode surface. Then,
26 the specific antigen attaches to the antibody, and the complex of
27 SPA-antibody-antigen is formed. The frequency shift (Δf) caused by the deposition of
28 proteins on the electrode surface can be related to the adsorbed mass (Δm). The
29 relationship between Δf and Δm is in accordance with the Sauerbrey equation, as
30 follows:
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

$$\Delta f = \frac{-2f_0^2 \Delta m}{A\sqrt{\rho_q \mu_q}}$$

46
47 where f_0 is the fundamental resonant frequency of the unloaded resonator
48 ($f_0=9 \times 10^6$ Hz), A is the piezoelectrically active area of the electrodes, and ρ_q and μ_q
49 are the density of quartz (2.648×10^3 kg m⁻³) and the shear modulus (2.947×10^{10} kg
50 m⁻¹s⁻²), respectively.
51
52
53
54
55
56

57 This study aimed to address a method that can lead to the simultaneous detection
58
59
60

1
2
3 of double antigens (AFP and HBsAg, evaluated as a standard biomarker of liver
4 cancer and hepatitis B, respectively). SPA was used as an intermediate to enhance the
5 site-orientation control rather than random adsorption during antibody immobilization.
6 After immunoreactions, the fluorescence signals of two kinds of fluorescence-labeled
7 antibodies can be obtained simultaneously using a fluorescence microscope. The
8 frequency and mass changes were used for real-time detection by QCM
9 immunosensor. Aside from immunoassay characteristics, surface characterization was
10 also investigated to validate the measurement of multiple protein biomarkers.

17 **Experimental**

19 **Materials**

20 Alpha fetoprotein (AFP), anti-AFP antibody, tetramethyl rhodamine isothiocyanate
21 (TRITC)-tagged anti-AFP antibody (Santa Cruz Biotechnology, Inc.), Hepatitis B
22 virus surface antigen (HBsAg), anti-Hepatitis B virus surface antigen antibody
23 (HBsAb), and fluorescein isothiocyanate (FITC)-tagged HBsAb (Biorbyt,
24 Cambridge, UK) were used throughout the study. SPA and His-SPA were purchased
25 from Axxora (San Diego, USA). Ni-NTA agarose beads (size: 45-165 μm) were
26 purchased from Qiagen. Acetone (AR) and absolute ethanol (AR) were purchased
27 from Xiangke Fine Chemical Factory (China). Concentrated sulfuric acid (98%) and
28 hydrogen peroxide (30%) were provided by Xing Kong Chemical Glass Co., Ltd.
29 (China). The organosilane reagent 3-aminopropyl triethoxysilane (APTES) and the
30 linker glutaraldehyde (GA), with solutions of 5% APTES in acetone and 5%
31 glutaraldehyde in Milli-Q water, respectively, were obtained from Sigma-Aldrich.
32 Phosphate-buffered saline (PBS, 10 mM, pH 7.2) was sterilized, preserved at 4 °C,
33 and used as a wash and dilution buffer. SPAs in the PBS solution were deployed at
34 1 mg/ml. All antibodies were diluted with PBS solution into 1 mg/ml and stored at
35 4 °C separately. A blocking buffer was prepared by dissolving bovine serum albumin
36 (BSA, Sigma Aldrich) in the PBS solution (containing 0.1% BSA). A washing buffer
37 was prepared by adding Tween-20 to the PBS solution (containing 0.05% Tween-20).

51 **Fluorescence microscope**

52 Ni-NTA beads were washed thrice with PBS buffer for 3 min at 400 r/min, and the
53 supernatant was then discarded. The Ni-NTA beads were incubated with 500 μl of
54 50 $\mu\text{g/ml}$ His-SPA solution for 12 h at 4 °C. After incubation, the beads were washed
55 thrice with PBS solutions for 3 min at 400 r/min to remove the unreacted His-SPA.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Afterward, the beads were incubated in 0.1% BSA solution (in PBS) with shocking for 4 h at 4 °C to block all available nonspecific binding sites, and then washed with PBS buffer to remove excess BSA. Second, Ni-NTA beads covered with His-SPA were immersed in 0.1 mg/ml antibody solutions with oscillation for 6 h at 4 °C. The beads were then incubated in antigen solutions with shocking for 6 h at 4 °C. Finally, the beads were immersed in fluorescence-labeled antibodies in the dark with shocking for 6 h at 4 °C. The samples after each step were rinsed by washing buffer thrice to remove the nonspecific adsorbed proteins. A cross-over experiment was then conducted following the same steps listed above, but using different fluorescence-labeled antibodies. The beads were stored in the dark at 4 °C until scanning.

A fluorescence microscope (MF30, Mshot Company) was used to capture the images of fluorescent signal emitted by labeled biomolecules bound to the beads. A filter system was used for blue excitation (excitation wavelength: 480 ± 40 nm) of FITC-tagged biomolecules and green excitation (excitation wavelength: 527 ± 30 nm) of TRITC-tagged complexes, which in turn emitted the green fluorescence and the red fluorescence, respectively.

Quartz crystal microbalance (QCM)

The QCM crystal was rinsed with acetone in an ultrasonic bath for 5 min and then washed with Milli-Q water. Afterward, the QCM crystal was dried in an N₂ gas stream, followed by absolute ethanol, before coating. To remove any organic contamination from the crystal surface and to improve the hydrophilic nature of the freshly prepared gold surface, the chip was treated by dipping into piranha solution (98% H₂SO₄/30% H₂O₂, 7:3 in v/v) for 5 min. Piranha solution has strong corrosive properties; great care should be taken to avoid any contact with the electrode welding points. After rinsing thoroughly with Milli-Q water and drying with nitrogen, the chip surface was hydrophilic. A 5% APTES solution in acetone was immediately added to the crystal surface for 1 h at room temperature. Afterward, the sample was rinsed with Milli-Q water and blown dry under a stream of N₂. The chip was placed in a 5% glutaraldehyde solution for 3 h to allow cross linking between the chip and the SPA.

Frequency shift was monitored and recorded in liquid media at room temperature. Previous experiments demonstrated that no significant shift of frequency occurred after adding 50 µg/ml of SPA solution prepared in PBS, thereby indicating the saturation of GA-(APTES)-modified quartz crystal with SPA solution at 50 µg/ml

1
2
3 protein concentration. This concentration was selected for all the subsequent
4 experiments thereafter. After the baseline obtained with PBS was stabilized, it was
5 rinsed with a buffer solution. When the frequency was stable, the QCM biosensor was
6 prepared for incubation in 0.1% BSA solution. After covering with BSA, the chip
7 blocked all available nonspecific binding sites that were not bound to the SPA on the
8 modified chip. The chip was then rinsed with PBS to wash off excess BSA. When the
9 frequency was stable, anti-AFP antibody (100 $\mu\text{g/ml}$) and HBsAb (100 $\mu\text{g/ml}$) were
10 added to the activated QCM crystal and rinsed with PBS buffer when the frequency
11 was stable. Only a small difference in frequency shift was observed between the
12 antibody concentrations (0.01-1 mg/ml). The concentration of the antibody was
13 optimized to 100 $\mu\text{g/ml}$ and then used for all subsequent experiments. A drop of AFP
14 protein (100 $\mu\text{g/ml}$) was introduced to the cell to measure the binding of the anti-AFP
15 antibody onto the SPA-coated surface, after which rinsing was done with PBS buffer.
16 Finally, HBsAg (100 $\mu\text{g/ml}$) was added to the chip surface to verify the binding of
17 HBsAb onto the chip surface; excess HBsAg was removed by rinsing with PBS buffer.
18 For each adsorption step, the same buffer (PBS solution) was flushed through the
19 chamber to remove the non-covalently bonded proteins; a QCM immunosensor was
20 prepared for detection. In the final step, the “sandwich” (SPA-antibody-antigen)
21 complex was formed, which was attached to the sensor surface. The process is
22 illustrated in Fig. 1. Measurements were conducted until a stable frequency
23 (frequency shift less than 3 Hz) was observed for >1 min. The amount of protein
24 bound to chip surface was determined with a QCM.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 A QCM (Maxtek, USA) with 9 MHz AT-cut quartz crystals (gold coated) was
41 used to quantitatively study the ability of proteins to bind to the chip. The gold surface
42 had a surface area for immobilization of 1.37 cm^2 . With the same protocol, the
43 proteins were linked on the QCM surface, and the mass sensitivity of the crystal was
44 calculated as 0.012 Hz/ng/cm^2 .
45
46
47

48 **Atomic Force Microscopy (AFM)**

49 AFM experiments were performed with atomic force microscope Agilent 5500. For
50 AFM studies, silicon substrates were prepared with the same modification techniques
51 as those described above for the QCM chips. Biomolecular imaging was conducted in
52 non-contact mode in air at room temperature. The AFM images were analyzed using
53 image processing software to calculate the root-mean-square roughness value and
54 maximum height (R_{max}). The average surface roughness (R_{a}) for each AFM image
55
56
57
58
59
60

1
2
3 was calculated using the PicoView^R software package provided with the instrument.
4

5 **Results and discussion**

6 **Fluorescence imaging**

7
8 His-SPA molecules were first immobilized on Ni-NTA agarose gel beads to prevent
9 random immobilization of the antibodies. Meanwhile, standard sandwich
10 immunoassay (antibody-antigen-antibody) was used on His-SPA coated Ni-NTA
11 beads. The existence of fluorescence confirmed the presence of respective immune
12 complexes on the beads surface. In this study, simultaneous detection of two kinds of
13 fluorescence-labeled antibodies can be realized by measuring the fluorescence signals.
14
15

16
17
18
19
20 Anti-AFP antibody labeled with TRITC exhibited appeared red light through
21 green light irradiation. In the presence of FITC-tagged HBsAb, green light was
22 obtained by measuring the blue light excitation spectra. The fluorescence images of
23 the two kinds of immune complexes are presented in Fig. 2. The existence of the
24 circular green regions was testified by the immunoreactions of the FITC-conjugated
25 HBsAb and HBsAg on the Ni-NTA beads, whereas the circular red regions were
26 confirmed by the immune reactions of the TRITC-conjugated anti-AFP antibody. As
27 shown in Fig. 2A and 2B, circular red and circular green regions were present on each
28 single bead. Fluorescence images demonstrated that the Ni-NTA beads both integrated
29 with anti-AFP antibodies, but also combined with HBsAb. According to Fig. 2B, the
30 Ni-NTA beads without His-SPA also combined with anti-AFP antibody and HBsAb.
31 However, the fluorescence intensity of the beads decreased in the absence of His-SPA.
32 As shown in Fig. 2C, after the Ni-NTA beads were blocked with BSA, the circular red
33 and circular green regions were hardly observed, suggesting two kinds of
34 immunocomplexes were not adsorbed on the beads.
35
36

37
38
39
40
41
42
43
44
45 As a control in the cross-over experiment, the fluorescence-labeled antibody
46 specifically bound to the Ni-NTA beads (Fig. 3). As shown in Fig. 3A and 3B, the
47 Ni-NTA beads emitted only one kind of fluorescence excited by light when the
48 fluorescence-labeled antibody bound to its specific antigen. It indicates that there is
49 no cross-reaction between antigens and antibodies. Fluorescence microscope is a
50 feasible tool for simultaneously detection of multiple biomarkers.
51
52

53
54
55
56
57
58
59
60 Furthermore, this approach was applied to diagnose double antigen biomarkers
in actual human serum samples, and the results were compared with commercial
ELISA kits. Densitometric analysis of the circular red/green regions was performed

1
2
3 with the software ImageJ 1.43m. Quantitative data based on the measurement of mean
4 intensity inside the circle were presented in Table 1. It shows that the proposal method
5 of synchronous fluorescence has acceptable and accurate results compared to the
6 AFP/HBsAg ELISA kit (AutoBio Diagnostics, China) in the detection of 12 serum
7 samples (4#, 5# and 6# containing analytes of both AFP and HBsAg). The LOD (limit
8 of detection, defined as the analyte concentration that is required to produce a signal
9 greater than three times of normal human serum value) of synchronous fluorescence is
10 found to be 0.5 and 0.2 ng/ml when detecting AFP and HBsAg respectively. In
11 contrast, the LOD of assay using AFP/HBsAg ELISA kit is just 2.5/0.5 ng/ml.

18 **Quartz crystal microbalance (QCM)**

19 The first immunoreaction occurred between SPA and antibody. SPA was immobilized
20 first on the chips to prevent the random immobilization of the antibodies. The chips
21 were subjected to an acidic treatment, followed by aqueous silanization, to increase
22 surface hydrophilicity, which would increase the ability to add functional groups. The
23 gold surface was then blocked by 0.1% BSA solution. The mixed solution of anti-AFP
24 antibody and HBsAb was added and reacted with the SPA-coated surface. After
25 antibody immobilization, the antigen solution was linked to the antibody. The typical
26 frequency changes of the quartz crystal functionalized with SPA as a result of a
27 cascade of interactions with antibodies and antigens are shown in Fig. 4. Point 1 refers
28 to when SPA solution (50 $\mu\text{g/ml}$) was allowed to react with the GA-APTES-modified
29 quartz crystal. The signal became stable only after 20 min. Point 2 indicates the event
30 wherein the crystal was subjected to several wash cycles. Point 3 was the time at
31 which the frequency of the crystal stabilized when all non-specifically adsorbed
32 molecules were rinsed away, and SPA was specifically bound on the surface. After
33 SPA binding step, 0.1% BSA solution was supposed to block any non-specific binding
34 (point 3) because it showed low affinities for antibodies. Point 4 was when the
35 solution comprising a mixture of anti-AFP antibody and HBsAb was added to the
36 crystal. The binding of the antibody to the immobilized SPA caused a decrease in the
37 resonant frequency, and stabilization occurred after 30 min. Point 5 corresponds to the
38 final resonant frequency after rinsing with PBS solution. The frequency shift for
39 antibody immobilization was found at 96.6 Hz. Point 5 refers to the time when
40 anti-AFP antigen solutions (100 $\mu\text{g/ml}$) were added to the chip surface. The frequency
41 shift was 47.1 Hz (point 6). For the final step, 100 $\mu\text{g/ml}$ HBsAg solution in PBS was
42 added, and after successive additions, the final frequency shift was 47.9 Hz (point 6).
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 These results indicated that two kinds of antibodies can simultaneously be
4 immobilized on the chip, and the antigen is not cross-reactive with the antibody.
5 According to the Sauerbrey relation, the adsorption amount of anti-AFP antibody and
6 HBsAb was calculated as 2.86 μg and 2.91 μg , respectively. The QCM sensor
7 revealed that using SPA as an intermediate for site-oriented immobilization can
8 accomplish simultaneous detection.
9

13 AFM

14 To obtain quantitative impression and estimate the uniformity of the surface
15 morphology, AFM topographies of three substrates were obtained, as follows:
16 APTES-modified crystal (Fig. 5A), SPA-coated crystal (Fig. 5B), and APTES + SPA
17 modified crystal. The AFM image of the APTES-modified crystal was affected by the
18 amount of crosslinking agent glutaraldehyde solution, as shown in Fig. 5A, which is
19 different from that in Fig. 5B and 5C. In comparison, the AFM topography of the
20 SPA-coated crystal surface (Fig. 5B) revealed that the gold-coated quartz crystals
21 showed a relatively smooth surface. The orientation of the SPA molecules is not
22 uniform. Hence, the active sites on one protein molecule may sterically hinder the
23 active sites on the other, resulting in a non-uniform binding of biomolecules and loss
24 of active sites. More active sites for antibody immobilization can result in improved
25 binding and higher sensitivity. The film in Fig. 5C was more uniform, with a
26 maximum height (R_{max}) of 200 nm, compared with the one shown in Fig. 5B. Thus,
27 these two approaches can be combined in such a way that the antibodies can be
28 immobilized on the crystal surface uniformly.
29
30
31
32
33
34
35
36
37
38
39

40 Conclusions

41
42 In this study, an *in vitro* detection method for simultaneous analysis of double antigen
43 biomarkers was presented and validated by the results obtained via fluorescence
44 microscopy and QCM biosensor in the presence of SPA. SPA acted as the control unit
45 to achieve oriented immobilization of the capture antibody. The AFM surface
46 morphology study revealed improvement in the roughness of the surface on which the
47 biomolecules were immobilized. Currently, rapid, sensitive, and simultaneous
48 detection of multiple biomarkers in complex biological samples is still a challenge for
49 clinical diagnostics.²³⁻²⁶ Integration of advances in oriented interfacial adsorption and
50 surface modification would offer a unique idea as a way to fabricate detection devices.
51 Those high-throughput, large-scale platforms, such as micro- or nano-chips, allow
52
53
54
55
56
57
58
59
60

1
2
3 parallel detection of thousands of addressable elements in a single experiment, are too
4 expensive and technically complex for routine clinical diagnostics.^{6,27-29} Alternatively,
5 most laboratories are capable of performing fluorescent microscopy or QCM easy and
6 convenient, the methods proposed in this paper can be taken as a practical supplement
7 of multiple-target analysis.
8
9
10

11 **Acknowledgements**

12
13
14 This work was supported by National Natural Science Foundation of China
15 (31270988, 21306161), Undergraduate Innovational Experimentation Program of
16 Xiangtan University (2014xtuxj40), Scientific Research Fund of Hunan Provincial
17 Education Department (13B120), China Postdoctoral Science Foundation
18 (2014M562118) and Hunan Provincial Natural Science Foundation of China
19 (2015JJ2133).
20
21
22
23
24

25 **References**

- 26
27
28 1 H. Mukundan, H. Xie, D. Price, J. Z. Kubicek-Sutherland, W. K. Grace, A. S.
29 Anderson, J. S. Martinez, N. Hartman and B. I. Swanson, *Anal. Chem.*, 2010, 82,
30 136-144.
31
- 32
33 2 J. M. Lee, J. J. Han, G. Altwerger and E. C. Kohn, *J. Proteomics*, 2011, 74,
34 2632-2641.
35
- 36
37 3 B. V. Chikkaveeraiah, A. A. Bhirde, N. Y. Morgan, H. S. Eden and X. Chen, *ACS*
38 *Nano*, 2012, 6, 6546-6561.
39
- 40
41 4 J. D. Wulfkuhle, L. A. Liotta and E. F. Petricoin, *Nat. Rev. Cancer*, 2003, 3,
42 267-275.
43
- 44
45 5 V. Kulasingam and E. P. Diamandis, *Nat. Clin. Pract. Oncol.*, 2008, 5, 588-599.
46
- 47
48 6 J. F. Rusling, C. V. Kumar, J. S. Gutkind and V. Patel, *Analyst*, 2010, 135,
49 2496-2511.
50
- 51
52 7 J. A. Ludwig and J. N. Weinstein, *Nat. Rev. Cancer*, 2005, 5, 845-856.
53
- 54
55 8 M. Ferrari, *Nat. Rev. Cancer*, 2005, 5, 161-171.
56
- 57
58 9 S. F. Kingsmore, *Nat. Rev. Drug. Discov.*, 2006, 5, 310-320.
59
- 60
61 10 R. Wei, G. J. Knight, D. H. Zimmerman and H. E. Bond, *Clin. Chem.*, 1977, 23,
62 813-815.
63
- 64
65 11 J. Shen, Y. Zhou, F. Fu, H. Xu, J. Lv, Y. Xiong and A. Wang, *Talanta*, 2015, 142,
66 145-149.

- 1
2
3 12 R. Xu, Y. Jiang, L. Xia, T. Zhang, L. Xu, S. Zhang, D. Liu and H. Song, *Biosens.*
4 *Bioelectron.*, 2015, 74, 411-417.
5
6 13 H. Dai, G. Xu, S. Zhang, L. Gong, X. Li, C. Yang, Y. Lin, J. Chen and G. Chen,
7 *Biosens. Bioelectron.*, 2014, 61, 575-578.
8
9 14 K. Nakanishi, T. Sakiyama, Y. Kumada, K. Imamura and H. Imanaka, *Curr.*
10 *Proteom.*, 2008, 5, 161-175.
11
12 15 B. Feng, C. Wang, X. Xie, X. Feng, Y. Li and Z. Cao, *Biochem. Biophys. Res.*
13 *Commun.*, 2014, 450, 429-432.
14
15 16 A. Makaraviciute and A. Ramanaviciene, *Biosens. Bioelectron.*, 2013, 50,
16 460-471.
17
18 17 M. Iijima, H. Kadoya, S. Hatahira, S. Hiramatsu, G. Jung, A. Martin, J. Quinn, J.
19 Jung, S. Y. Jeong, E. K. Choi, T. Arakawa, F. Hinako, M. Kusunoki, N.
20 Yoshimoto, T. Niimi, K. Tanizawa and S. Kuroda, *Biomaterials*, 2011, 32,
21 1455-1464.
22
23 18 A. Kaushansky, J. E. Allen, A. Gordus, M. A. Stiffler, E. S. Karp, B. H. Chang
24 and G. MacBeath, *Nat. Protoc.*, 2010, 5, 773-790.
25
26 19 J. Zhou, L. Du, L. Zou, Y. Zou, N. Hu and P. Wang, *Sens. Actuators B Chem.*,
27 2014, 197, 220-227.
28
29 20 M. J. Oliver, J. Hernando-García, P. Pobedinskas, K. Haenen, A. Ríos and J. L.
30 Sánchez-Rojas, *Colloids Surf. B Biointerfaces*, 2011, 88, 191-195.
31
32 21 D. Matatagui, J. Fontecha, M. J. Fernández, M. J. Oliver, J. Hernando-García, J.
33 L. Sánchez-Rojas, I. Gràcia, C. Cané, J. P. Santos and M. C. Horrillo, *Sens.*
34 *Actuators B Chem.*, 2013, 189, 123-129.
35
36 22 N. S. K. Gunda, M. Singh, L. Norman, K. Kaur and S. K. Mitra, *Appl. Surf. Sci.*,
37 2014, 305, 522-530.
38
39 23 G. J. Zhang, Z. H. Luo, M. J. Huang, J. J. Ang, T. G. Kang and H. Ji, *Biosens.*
40 *Bioelectron.*, 2011, 28, 459-463.
41
42 24 H. C. Tekin and M. A. Gijs, *Lab Chip*, 2013, 13, 4711-4739.
43
44 25 B. A. Otieno, C. E. Krause, A. Latus, B. V. Chikkaveeraiah, R. C. Faria and J. F.
45 Rusling, *Biosens. Bioelectron.*, 2014, 53, 268-274.
46
47 26 L. Xiong, L. Gao, Q. Liu, J. Xia, X. Han and Y. Liu, *Anal. Methods*, 2013, 5,
48 2413-2418.
49
50 27 S. Baratchi, K. Khoshmanesh, C. Sacristán, D. Depoil, D. Wlodkowic, P.
51 McIntyre and A. Mitchell, *Biotechnol. Adv.*, 2014, 32, 333-346.
52
53
54
55
56
57
58
59
60

- 1
2
3 28 S. A. Svarovsky and L. Joshi, *Anal. Methods*, 2014, 6, 3918-3936.
4
5 29 S. J. Maerkl, *Curr. Opin. Biotechnol.*, 2011, 22, 59-65.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Evaluation and comparison of synchronous fluorescence with traditional ELISA in serodiagnosis

Method	Analyte	AFP (+)			AFP (+)/HBsAg (+)			HBsAg (+)			Normal human serum			LOD ng/ml
		1#	2#	3#	4#	5#	6#	7#	8#	9#	10#	11#	12#	
Synchronous fluorescence ^a (Mean Dens)	AFP	150	173	198	242	250	207	12.2	10.5	14.3	8.07	7.58	9.13	0.5
	HBsAg	12.8	10.5	7.40	255	239	248	213	245	255	6.97	10.4	8.61	0.2
Traditional ELISA ^b (Mean A ₄₅₀)	AFP	0.35	0.54	0.71	1.24	1.38	0.76	0.02	0.01	0.01	0.02	0.01	0.02	2.5
	HBsAg	0.02	0.02	0.01	1.68	1.25	1.34	0.72	1.39	1.66	0.00	0.01	0.01	0.5

^a The resulting images were loaded into the software ImageJ 1.43m and transformed into 8-bit color ones (Image→Color→Split channels). The 8-bit red and green fluorescent-channel images were then ready for further quantification. A circle enclosing the Ni-NTA bead in the brightfield image was drawn by using the “Elliptical selection” tool. The average intensity inside the circle (expressed as Mean Dens) was measured image by image (Analyze→Measure). ^b ELISA protocol: 50 µl serum sample and 50 µl horseradish peroxidase-conjugated anti-AFP/ anti-HBs were added to each well of microplates. After 30 min incubation at 37 °C, the plates were washed to remove any unbound conjugate and developed with the substrate tetramethylbenzidine for 5 min. The colorimetric reaction was terminated by addition of 50 µl of 2 M H₂SO₄ and absorbance value was measured at 450 nm by using a model 550 microplate reader (Bio-Rad, USA). All tests were repeated four times and the arithmetic mean of absorbance values (A₄₅₀) was presented. 12 representative serum samples (4#, 5# and 6# containing analytes of both AFP and HBsAg) were obtained from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). The LOD (limit of detection) is defined as the analyte concentration that is required to produce a signal greater than three times of normal human serum value.




Fig. 1 Schematic of the site-oriented immobilization of antibodies onto the chip surface using SPA as an intermediate. The experimental procedures involves: a) substrate cleaning (piranha cleaning); b) treatment with APTES (5%) and glutaraldehyde (5%) solutions; c) immobilization of capture antibodies; and d) immobilization of antigen biomolecules.




Fig. 2 Fluorescence images of the Ni-NTA agarose beads were obtained by FL microscopy, with green light (+) and blue light (-) excitation spectra. The beads were integrated with two kinds of immunocomplexes, as follows: (A) both anti-AFP antibody and HBsAb integrated with fluorescence-labeled specific secondary antibodies blocked with BSA in the presence of His-SPA; (B) both anti-AFP antibody and HBsAb integrated with fluorescence-labeled specific secondary antibodies blocked with BSA in the absence of His-SPA; (C) Ni-NTA beads were blocked with BSA, then both anti-AFP antibody and HBsAb integrated with fluorescence-labeled specific secondary antibodies were incubated with beads in the presence of His-SPA.




Fig. 3 Fluorescence images of Ni-NTA agarose beads were obtained by FL microscopy, with green light (+) and blue light (-) excitation spectra in the cross-over experiment. The beads were integrated together with (A) HBsAb, HBsAg, and FITC-conjugated HBsAb, along with TRITC-conjugated anti-AFP antibody; (B) anti-AFP antibody, AFP protein, and TRITC-conjugated anti-AFP antibody, along with FITC-conjugated HBsAb.




Fig. 4 QCM frequency responses for the addition of specific antibodies and antigens to the SPA modified quartz crystal.




Fig. 5 AFM topographic images of antibodies immobilized on the gold surface. (A) APTES-modified crystal; (B) SPA-coated crystal; and (C) APTES + SPA modified crystal.